BPC-157 counteracts L-NAME-induced catalepsy and mitigates schizophrenia-like symptoms in rat models

Schizophrenia presents a complex therapeutic challenge, with current treatments often focusing on dopamine and glutamate pathways. The nitric oxide (NO) system has also been implicated in its pathophysiology, but its precise role remains unclear. Schizophrenia-like symptoms, such as disturbed motor activity and catalepsy, can be modeled in animals using various pharmacological agents. For instance, dopamine antagonists like haloperidol induce catalepsy, while agents like amphetamine, apomorphine, and MK-801 can induce hyperactivity or sensitization, mimicking 'positive-like' symptoms. L-NAME, an inhibitor of nitric oxide synthase (NOS), and L-arginine, an NOS substrate, are tools used to probe the NO system's involvement. The stable gastric pentadecapeptide BPC-157 is being investigated for its potential neuroprotective and modulatory effects across various systems, including its interaction with the dopaminergic and NO pathways, offering a novel angle for addressing these complex symptoms.

Researchers used rat models to investigate schizophrenia-like symptoms. They administered medications intraperitoneally (i.p.) 5 min before challenges. Acute models involved inducing motor disturbances with amphetamine (3.0 mg/kg), apomorphine (2.5 mg/kg), or MK-801 (0.2 mg/kg), and catalepsy with haloperidol (2.0 mg/kg). The primary interventions were BPC-157 (0.01 mg/kg), L-NAME (5 mg/kg), and L-arginine (100 mg/kg), given alone or in combination. In another acute model, BPC-157 (10 μg/kg) was given immediately after a high dose of L-NAME (40 mg/kg). A chronic model used methamphetamine administration for 3 days during the first 3 weeks to induce sensitization, with a challenge after 4 weeks. Interventions were given before methamphetamine during the second and third weeks. The primary endpoints were the counteraction of induced motor disturbances, catalepsy, and sensitization.

BPC-157, given alone, effectively counteracted the effects of amphetamine, apomorphine, MK-801, haloperidol-induced catalepsy, and chronic methamphetamine-induced sensitization. L-arginine showed similar counteracting effects. In contrast, L-NAME only counteracted the acute amphetamine effect and did not affect the others. Critically, BPC-157's therapeutic effect was maintained even in the presence of NOS blockade by L-NAME. When L-NAME was co-administered with L-arginine, it nullified L-arginine's benefits in most models, demonstrating an NO-specific interaction. However, BPC-157's efficacy was not diminished by L-NAME co-administration. Furthermore, BPC-157 was able to restore the counteracting effect of L-arginine even when L-NAME was present (L-NAME + L-arginine + BPC-157).

Most notably, BPC-157 was shown to directly inhibit the catalepsy induced by a high dose of L-NAME, demonstrating a potent effect independent of the typical NO-substrate pathway. This suggests BPC-157's mechanism operates distinctly from the L-arginine/NO-synthase pathway, allowing it to bypass NOS inhibition and still exert a corrective influence on dopamine and glutamate system disruptions.

Written by TitrateLab, separately from the study summarized above.